1-3 of 3
Liping Laura Sun
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Interim Report on a Phase 1/2 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC ® ) Targeting B Cell Maturation Antigen for the Treatment of Relapsed/Refractory Multiple Myeloma

Sumit Madan, Al-Ola Abdallah, Andrew J. Cowan, William I. Bensinger, Jens Hillengass, Xavier Leleu, Eva Medvedova, Caitlin Costello, Brea Lipe, Henning Schade, Rajneesh Nath, Liping Laura Sun
Journal: Blood
Blood (2021) 138 (Supplement 1): 1654.
https://doi.org/10.1182/blood-2021-148176
Published: 2021
Journal Articles

HPN217-3001: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217, a Bcma-Targeting T-Cell Engager, in Patients with Relapsed/Refractory Multiple Myeloma

Henning Schade, MD, Sumit Madan, MD, Eva Medvedova, MD, Rajneesh Nath, MD, Lisa Knapp, Bryan Lemon, PhD, Liping Laura Sun, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 10.
https://doi.org/10.1182/blood-2020-136012
Published: 2020
Journal Articles

Preclinical Characterization of Combinability and Potential Synergy of Anti-CD20/CD3 T-Cell Dependent Bispecific Antibody with Chemotherapy and PD-1/PD-L1 Blockade

Liping Laura Sun, PhD, Peiyin Wang, Robyn Clark, Maria Hristopoulos, Diego Ellerman, PhD, Mary Mathieu, Yu-Waye Chu, Hong Wang, PhD, Klara Totpal, PhD, Allen J. Ebens, PhD, Andrew G. Polson, PhD, Stephen Gould, PhD
Journal: Blood
Blood (2016) 128 (22): 4168.
https://doi.org/10.1182/blood.V128.22.4168.4168
Published: 2016